"The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx." by Lauren Carcas

Article

The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx.

Journal of Clinical Oncology (2015)

Lauren Carcas
Jessica Macintyre
Jaime R. Merchan
Peter Joel Hosein
Ikechukwu Immanuel Akunyili
Maria Restrepo
Monica T. Garcia
Lorraine Portelance
Danny Sleeman
Joe U Levi
Caio Max S. Rocha Lima

Link

Disciplines

Publication Date

January 20, 2015

DOI

10.1200/jco.2015.33.3_suppl.460

Citation Information

Lauren Carcas, Jessica Macintyre, Jaime R. Merchan, Peter Joel Hosein, et al.. "The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx." Journal of Clinical Oncology Vol. 33 (2015) p. 460 - 460
Available at: http://works.bepress.com/lauren-carcas/3/